Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: A randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder

Clinical Therapeutics

Volumn 32, Issue 3, 2010, Pages 472-491

  Miceli, Jeffrey J ^a   Tensfeldt, Thomas G ^a   Shiovitz, Thomas ^b   Anziano, Richard J ^a   O'Gorman, Cedric ^c   Harrigan, Rachel H ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b California Neuroscience Research Medical Group Inc   (United States)

^c PFIZER INC   (United States)

Author keywords

Atypical antipsychotics; Intramuscular; QT interval; Schizophrenia

Indexed keywords

HALOPERIDOL; ZIPRASIDONE;

ADULT; AGED; AGITATION; ANXIETY; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; EXTRAPYRAMIDAL SYNDROME; FEMALE; HEART RATE; HUMAN; HYPOTENSION; INJECTION SITE PAIN; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PARALLEL DESIGN; PHASE 1 CLINICAL TRIAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOMNOLENCE; SWEATING; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; XEROSTOMIA;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; HALOPERIDOL; HEART RATE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SINGLE-BLIND METHOD; THIAZOLES; YOUNG ADULT;

EID: 77951905580     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.03.003     Document Type: Article

References (30)

1. Currier GW, Trenton A Pharmacological treatment of psychotic agitation. CNS Drugs 2002, 16:219-228.
2. Milton GV, Jann MW Emergency treatment of psychotic symptoms. Pharmacokinetic considerations for antipsychotic drugs. Clin Pharmacokinet. 1995, 28:494-504.
3. Foster S, Kessel J, Berman ME, Simpson GM Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. Int Clin Psychopharmacol. 1997, 12:175-179.
4. King DJ, Burke M, Lucas RA Antipsychotic drug-induced dysphoria. Br J Psychiatry. 1995, 167:480-482.
5. Brook S A pilot study of intramuscular ziprasidone in the short-term treatment of patients with acute exacerbation of schizophrenia. Hum Psychopharmacol. 2000, 15:521-524.
6. Daniel DG, Potkin SG, Reeves KR, et al. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: A double-blind, randomized trial. Psychopharmacology (Berl). 2001, 155:128-134.
7. Lesem MD, Zajecka JM, Swift RH, et al. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients [published correction appears in J Clin Psychiatry. 2001;62:209]. J Clin Psychiatry 2001, 62:12-18.
8. Brook S, Walden J, Benattia I, et al. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: Comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology (Berl). 2005, 178:514-523.
9. Zimbroff DL, Brook S, Benattia I Poster Session. Safety and tolerability of IM ziprasidone: Review of clinical trial data. Eur Neuropsychopharmacol. 2002, 12(Suppl 3):294.
10. Overall JE, Gorham DR The Brief Psychiatric Rating Scale. Psychol Rep. 1962, 10:799-812.
11. Glassman AH, Bigger JT Antipsychotic drugs: Prolonged QTc interval, torsades de pointes, and sudden death. Am J Psychiatry. 2001, 158:1774-1782.
12. Taylor D Ziprasidone in the management of schizophrenia: The QT interval issue in context. CNS Drugs. 2003, 17:423-430.
13. Bednar MM, Harrigan EP, Anziano RJ, et al. The QT interval. Prog Cardiovasc Dis. 2001, 43(Suppl 1):1-45.
14. Moss AJ QTc prolongation and sudden cardiac death: The association is in the detail. J Am Coll Cardiol. 2006, 47:368-369.
15. Straus SM, Kors JA, De Bruin ML, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol. 2006, 47:362-367.
16. Viskin S Long QT syndromes and torsades de pointes. Lancet. 1999, 354:1625-1633.
17. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol. 2004, 24:62-69.
18. Briefing document for Zeldox capsules (Ziprasidone HCI) Pfizer Inc, FDA Psychopharmacological Drugs Advisory CommitteeFDA Psychopharmacological Drugs Advisory Committee, Accessed September 16, 2008. http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3619b1a.pdf.
19. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005, 353:1209-1223. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators.
20. Stöllberger C, Huber JO, Finsterer J Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol. 2005, 20:243-251.
21. Daniel DG, Zimbroff DL, Swift RH, Harrigan EP The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy. Int Clin Psychopharmacol. 2004, 19:9-15.
22. Briefing document for Ziprasidone Mesylate for intramuscular injection Pfizer Inc, FDA Psychopharmacological Drugs Advisory CommitteeFDA Psychopharmacological Drugs Advisory Committee, Accessed September 18, 2008. http://www.fda.gov/ohrms/dockets/AC/01/briefing/3685b2_01_pfizer.pdf.
23. Geodon [prescribing information] 2008, Pfizer Inc, New York, NY.
24. Haldol [prescribing information] 2001, Ortho-McNeil Pharmaceuticals, Inc, Raritan, NJ.
25. Freedman D, Pisani R, Purves R Statistics 2007, WW Norton, New York, NY. 4th ed.
26. The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs International Conference on Harmonisation, Accessed February 12, 2010. http://www.ich.org/cache/compo/475-272-1.html#E14.
27. Haddad PM, Anderson IM Antipsychotic-related QTc prolongation, torsades de pointes and sudden death. Drugs. 2002, 62:1649-1671.
28. Correll CU, Frederickson AM, Figen V, et al. The QTc interval and its dispersion in patients receiving two atypical antipsychotics. Eur Arch Psychiatry Clin Neurosci. 2009, 259:23-27.
29. Strom BL, Faich GA, Reynolds RF, et al. The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): Design and baseline subject characteristics. J Clin Psychiatry. 2008, 69:114-121.
30. Brook S, Lucey JV, Gunn KP Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. J Clin Psychiatry. 2000, 61:933-941. Ziprasidone I.M. Study Group.